Tag : Panaxia

CCT Impact

Panaxia continues growth: sums up 1st half of 2021 with 37.3 million revenues, 38.4% growth in comparison to 2020

CCT IMPACT Agent
The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), a global pharma company that develops, manufactures and markets progressive medical cannabis products in pharmaceutical quality, published today its financial reports for the second quarter and first half of 2021. Panaxia Israel – Revenues (Millions): Median Revenues 2019-2021......
CCT Impact

Panaxia and Neuraxpharm Expands Strategic Collaboration to Poland

CCT IMPACT Agent
Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), a global pharma company, specializes in developing, manufacturing and marketing advanced medical cannabis products in pharmaceutical quality and its partner, Neuraxpharm, Europe’s leading Pharma Company focused on the treatment of Central Nervous System (CNS) disorders, announced today expanding their strategic collaboration into the Polish market. The companies......
CCT Impact

Unprecedented Achievement in the Medical Cannabis Market: Panaxia and Neuraxpharm will be the first companies to exclusively launch Medical Cannabis Extracts for Inhalation in Europe

CCT IMPACT Agent
Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), a global pharma company, specializes in developing, manufacturing and marketing advanced medical cannabis products in pharmaceutical quality, and its German partner, Neuraxpharm, a leading European pharmaceutical company, specialized in the central nervous system (CNS), announced the receipt of a first of its kind regulatory permit from......
CCT Impact

Panaxia and Leriva announced: Exclusive collaborations in Greece

CCT IMPACT Agent
Panaxia Labs Israel, Ltd. (Panaxia Israel) (TASE: PNAX), Israel’s leading medical cannabis products manufacturer and Leriva Group, one of Greece’s leading distributors of medical equipment, medical supplies and health services, announced today, Wednesday May 19, 2021, a binding agreement of manufacture, commercialization and distribution of medical cannabis finished products, developed by Panaxia for medical cannabis patients in Greece.......
CCT Impact

Panaxia Israel announces estimated record revenues of at least 19 million in Q1 2021

CCT IMPACT Agent
The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. (“Panaxia Israel”) (TASE: PNAX), Israel’s largest manufacturer of medical cannabis products, today announced its estimated revenues for the first quarter of 2021. According to Panaxia’s estimates, its consolidated (unaudited) revenues for the first quarter of 2021 are expected to reach no less than 19 million.......
CCT Impact

Unprecedented international achievement for Panaxia: selected as one of the four main winners in the French government tender for regulation of the medical cannabis industry

CCT IMPACT Agent
Dr. Dadi Segal, CEO of Panaxia Global, said, “Our success in this prestigious French government tender along with our partner, Neuraxpharm, is a huge achievement for Panaxia, and we are proud to be part of the elite group of global medical cannabis leaders selected for the program. The fact that four......
CCT Impact

Panaxia continues its upward trend: Ends Q3 with record revenues of 16.8 million and 300% growth over the previous year

CCT IMPACT Agent
The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. (“Panaxia Israel”) (TASE: PNAX), Israel’s largest manufacturer of medical cannabis products, today announced its financial results for the third quarter and first nine months of 2020. Panaxia Israel – revenues in millions: 2018-2020 quarterly revenues (PRNewsfoto/Panaxia Pharmaceutical Industries) Dr. Dadi Segal, Founder and CEO of Panaxia said, “We......
CCT Impact

Panaxia is the first Israeli company to receive a marketing permit for medical cannabis products in Germany

CCT IMPACT Agent
The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. (Panaxia Israel) (TASE: PNAX), Israel’s largest medical cannabis manufacturer and Neuraxpharm, its partner, Europe’s largest pharmaceutical company in the field of the central nervous system (CNS),  announced on Sunday the completion of the registration process and receipt of final regulatory approval from the health authorities in Germany, Europe’s largest and fastest-growing......
Market Watch

Panaxia Global Reports: Panaxia Israel Continues to Grow

CCT IMPACT Agent
The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. (Panaxia Israel) (TASE: PNAX), the largest manufacturer of medical cannabis products in Israel, today reported the financial results for the second quarter and first half of 2020. Quarterly revenues, 2018-2020, in millions Dr. Dadi Segal, CEO of Panaxia Global, said, “The past six months have been......
CCT Impact

Panaxia’s agreement with international pharma Neuraxpharm is finalized

CCT IMPACT Agent
Neuraxpharm, a leading European pharmaceutical company specialized in CNS, and Panaxia Global, the controlling owner of Panaxia Labs Israel (Panaxia Israel) (TASE: PNAX), Israel’s largest medical cannabis manufacturer, announced today they have entered a definite agreement to start a business collaboration for marketing Panaxia’s medical cannabis products in Germany, Europe’s largest and fastest-growing market for cannabis......